Multiple myeloma trials in Poland

In Poland 38 Also abroad 703

38 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Where
Bydgoszcz, Cracow, Katowice, Lodz, Opole, Skorzewo, Torun
Age
18 years and over
People
78 worldwide
Run by
Heidelberg Pharma AG
See details and how to joinNCT04879043 · EU 2024-515273-10-00
Phase 3Not yet taking people in Poland
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
Where
Gdansk, Gliwice, Kielce, Lublin, Poznan, Wroclaw
Age
18 years and over
People
234 worldwide
Run by
AstraZeneca AB
See details and how to join2025-524014-29-00 · EU 2025-524014-29-00
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Bydgoszcz, Gdansk, Katowice, Poznan, Skorzewo, Warsaw, Wroclaw
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 1/2Taking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Lublin, Wroclaw
Age
18 years and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
Phase 3Taking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Gdansk, Gliwice, Kielce, Lublin, Poznan, Wroclaw
Age
18 years and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
Phase 3Taking people
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
Where
Gdansk, Gliwice, Lublin, Poznan, Warsaw, Wroclaw
Age
18 years and over
People
153 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523285-25-00 · EU 2025-523285-25-00
Phase 2Not yet taking people in Poland
Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
Where
Bydgoszcz, Gdansk, Katowice, Lodz, Poznan, Walbrzych, Warsaw, Wroclaw
Age
18 years and over
People
228
Run by
Polish Myeloma Consortium
See details and how to joinNCT07748689 · EU 2025-525096-83-00
Phase 3Not yet taking people in Poland
A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease
Where
Bydgoszcz, Gliwice, Katowice, Kielce, Lodz, Lublin, Poznan, Warsaw
Age
18 years and over
People
248
Run by
Polish Myeloma Consortium
See details and how to joinNCT07740486 · EU 2025-525097-11-00
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Lublin, Poznan, Warsaw
Age
18 years and over
People
88 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00
Phase 2Taking people
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Where
Cracow, Gdansk, Kielce, Lodz, Torun, Walbrzych
Age
18 years and over
People
116 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06140524 · EU 2023-505242-25-00
Phase 3Taking people
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Where
Lodz, Lublin, Walbrzych, Warsaw
Age
18 years and over
People
520 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06679101 · EU 2024-516030-35-00
No phaseTaking people
Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency
Where
Szczecin
Age
18 years and over
People
75 worldwide
Run by
Takeda
See details and how to joinNCT05879757
No phaseTaking people
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
Where
Gdansk
Age
18 years and over
People
100
Run by
Medical University of Gdansk
See details and how to joinNCT07270263